Year: 2020

  • WRAP Retail Offer for up to £500,000

    WRAP Retail Offer for up to £500,000 ImmuPharma Plc is pleased to announce a retail offer via the Winterflood Retail Access Platform (“WRAP”) to raise up to £500,000 (the “WRAP Retail Offer”) through the issue of new ordinary shares of 1 pence each in the capital of the Company (“Ordinary Shares”).  Under the WRAP Retail…

  • INTERIM RESULTS for the six months ended 30 June 2023

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2023 (the “Period”). Key Highlights (including post Period review) Financials Loss for the Period of £0.8m (30 June 2022:  £1.7m) Research and development expenses of £0.8m (30 June 2022: £1.0m) Administrative expenses…

  • Extension of Warrants in Incanthera plc

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that the Company has agreed with Incanthera plc (“Incanthera”) that Warrants issued to the Company on 26 February 2020, in conjunction with Incanthera’s IPO onto the Aquis Exchange, are extended by 12 months.  Key highlights: The Company entered into a Warrant…

  • Board strengthened Ahead of next phase of company progression

    ImmuPharma PLC (LSE:IMM),  the specialist drug discovery and development company, provides notification of changes to its Board of Directors. It has been a pivotal 2023 for ImmuPharma, specifically within its P140 autoimmune platform. Most recently in June, the Company announced that, after receiving comprehensive guidance from the Food & Drug Administration (“FDA”) on the new…

  • 2023 Result of Annual General Meeting – All Resolutions Passed

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below. Resolution For % For Against % Against Withheld 1. To receive the accounts of the Company for the year…

  • Proactive

    Proactive – ImmuPharma “delighted” to push on with new clinical trial 28 June 2023 ImmuPharma “absolutely delighted” to push on with new clinical trial.

  • Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in Lupus to commence following FDA meeting

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that the Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in patients with systemic lupus erythematosus (“SLE/Lupus”) is to commence in H2 2023.  Key highlights: Following the receipt of comprehensive guidance from the Food and Drug Administration (“FDA”) in 3 separate…

  • Immupharma PLC Warrants Outstanding

    To view warrants outstanding click here

  • Notice of AGM & Annual Report & Accounts

    ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting (“AGM”) has today been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2022 has also been posted to shareholders today. These documents will be available shortly, in electronic form,…

  • Proactive – Tim McCarthy

    Proactive – ImmuPharma “looking forward” with quiet confidence” to FDA response 24 May 2023 Tim McCarthy, CEO of ImmuPharma talks to Proactive Investors on the recent positive guidance from the FDA on its autoimmune program, CIDP – 24 May 2023